/
Unless the context otherwise requires, we , us , and our , the Company , Lucid and Lucid Diagnostics refer to Lucid Diagnostics Inc. and its subsidiaries LucidDx Labs Inc. ( LucidDx Labs ) and CapNostics, LLC ( CapNostics ). Background and Overview Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company.
The business is unprofitable at the operating level (-1054.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 8.3%, steady but not accelerating.
Negative free cash flow of -$47M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$5M
▲ +8.3% YoY
Net Income (TTM)
-$45M
▼ -27.4% YoY
Op. Margin
-959.62%
▲ +4.8pp YoY
ROIC
-276.31%
▲ +401.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$46M
▼ -5.1% YoY
Op. Cash Flow (TTM)
-$46M
▼ -5.3% YoY
Net Debt
-$26M
Net Cash Position
Cash & Equiv.
$28M
3Y CAGR: +132.0%
Continue Research